AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026.
Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company’s financial strategy, capital markets activities, and overall financial operations.
Anne Johnson, who has served as Chief Financial Officer since 2024, will transition to the role of Chief Accounting Officer upon the effective date of Mr. Faerm’s appointment. In this position, she will continue to lead accounting and financial operations, working closely with Mr. Faerm to ensure continuity and operational consistency.
“We are delighted to welcome Mike Faerm to AtaiBeckley as our Chief Financial Officer,” said Srinivas Rao, Chief Executive Officer and Co-Founder of Atai Beckley. “Mike brings deep strategic finance experience and a strong understanding of the life sciences sector, which will be important as BPL-003 moves toward Phase 3 and our broader clinical-stage programs continue to advance.”
“We also appreciate Anne’s continued leadership as Chief Accounting Officer. Her operational expertise and familiarity with our financial systems provide important continuity. Together, Mike and Anne create a strong and complementary finance leadership structure for the Company.”
“I’m excited to join AtaiBeckley at this important stage,” said Mr. Faerm. “With BPL-003 advancing toward Phase 3 and a strong clinical-stage pipeline supporting the broader strategy, this is a compelling time to help shape the Company’s financial and capital markets approach. I look forward to leading our financial strategy, partnering with Anne in her role as Chief Accounting Officer, and working closely with the full leadership team to support disciplined execution as the Company moves into late-stage development.”
Mr. Faerm most recently served as Chief Financial Officer at Viracta Therapeutics, Inc. Previously, he was Interim Chief Financial Officer at Harpoon Therapeutics, Inc., which was acquired by Merck, and where he helped lead a $150 million PIPE financing, and Chief Financial Officer of Artiva Biotherapeutics, Inc. Prior to those roles, Mr. Faerm served as the Chief Business Officer of Innoviva, Inc., and earlier, worked in business development and strategic finance roles at Forest Laboratories, Inc. and Regeneron Pharmaceuticals, Inc. Mr. Faerm’s Wall Street experience includes Credit Suisse and Wells Fargo Securities, where he was a senior equity research analyst covering the pharmaceutical sector, and Merrill Lynch, where he was an investment banker executing a wide range of mergers and acquisitions and financing transactions in the biopharma and other healthcare sectors. Mr. Faerm earned an MBA from Harvard Business School, an MS in Civil Engineering from Stanford University, and a BS in Civil Engineering from Columbia University.
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Calm" Becomes the New Normal for Forex Markets: Selling Volatility and Engaging in Carry Trades, but Institutions Warn of Potential "Time Bombs"
The "nothing will happen" mode is becoming the new normal for foreign exchange traders.
Bitcoin weathers September storm as rate hikes and Clarity act setback test bulls
Continuous mineralization over 905 meters! Auro Metals gold and copper resource potential is further confirmed, phase II drilling empowers long-term growth
Auro Metals Inc. has announced another major exploration breakthrough, with the first phase of drilling at the Santa Barbara copper-gold mine yielding further breakthrough results.
JP Morgan: Raising interest rates is not enough to end the US stock market rally; long-term rates, fiscal policies, and geopolitics are the real risks
J.P. Morgan believes that an interest rate hike does not signify the end of the bullish logic for US stocks, as AI capital expenditures and corporate profits can still support the equity market. However, fiscal deficits, bond supply, and geopolitical risks will continue to drive up long-term interest rates. The real concern is the rapid approach of the 10-year US Treasury yield to 5.5%-6%, at which point high-valuation growth stocks could face significantly increased pressure.
